Lumen appoints former Microsoft CMO Chris Capossela to board of directors

Lumen Technologies, Inc.

Board increased from 11 to 12 members; Capossela's appointment effective October 29, 2024.
Capossela served as Microsoft EVP and CMO for 10 years, leading worldwide marketing.
He will serve on the human resources/compensation committee and audit committee.
Receives prorated restricted stock grant with target value of $100,000, vesting in one year.
Will stand for reelection at the 2025 annual shareholders meeting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher Capossela

Director

LUMN · Lumen Technologies, Inc.

Effective: 2024-10-29
Filed: October 29, 2024, 7:59 PM ET

On October 29, 2024, the board of directors (the “Board”) of Lumen Technologies, Inc. (the “Company”), on the recommendation of its nominating and corporate governance committee, voted to increase its size from 11 members to 12 members and to appoint Christopher Capossela to fill the newly-created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Capossela was appointed as Director at Lumen Technologies, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 29, 2024, the board of directors (the “Board”) of Lumen Technologies, Inc. (the “Company”), on the recommendation of its nominating and corporate governance committee, voted to increase its size from 11 members to 12 members and to appoint Christopher Capossela to fill the newly-created vacancy.

View on SEC.gov

Lumen Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-246216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.